Pixium Vision - Three-year data confirms continued Prima safety
Pixium reported 36-month data from its European feasibility study (PRIMA-FS) on the Prima implant in patients with geographic atrophy (GA) associated with advanced dry age-related macular degeneration (Dry-AMD). The implant remained safe and well tolerated and, importantly, there was no indication of device or performance degradation, and patients continued to be capable of integrating their natural vision with the artificial vision provided by the device. We remain encouraged that there is no degradation in Prima’s prosthetic visual performance, given some external speculation that advanced Dry-AMD could eventually provoke atrophic damage to the retinal ganglion cells (on which the Prima system relies for providing the patient’s prosthetic vision).Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.